Repligen (RGEN) Stock Forecast & Price Target

Repligen has demonstrated strong financial growth, with a greater than 20% year-over-year increase in revenues from both contract development and manufacturing organizations (CDMOs) and biopharmaceutical customers. The company has raised its full-year 2025 revenue guidance to a range of $715-735 million, improving from the prior estimate of $695-720 million, indicating positive momentum in its business outlook. Additionally, revenues and order volumes have seen double-digit growth across all product franchises, with Process Analytics revenue specifically surging by more than 50% year-over-year, reflecting robust demand for Repligen's offerings in the bioprocessing sector.

Repligen has lowered its forecast for key financial metrics, adjusting the 2025 adjusted operating margin to approximately 13.5% and the adjusted EBITDA margin to about 19%, which indicates a less favorable outlook for profit generation. The company's expected adjusted EPS of $1.65-$1.68 highlights potential challenges in sustaining growth, especially if lingering concerns about product technology and defects arise, which could lead to lost revenue and increased costs. Additionally, a significant reduction in orders from large customers could adversely affect Repligen's financial condition and operational results, compounding the negative sentiment surrounding the company's future performance.